- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04388826
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a multicenter, randomized, placebo-control, efficacy and safety study of VERU-111 for the treatment of COVID-19. Subjects will receive either 18 mg of VERU-111 or matching placebo orally or through nasogastric tube daily for to 21 days or until the subject is discharged from the hospital, whichever comes first.
The primary efficacy endpoint of the study will be the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).
The total study duration for a subject from screening to follow up visit is planned to be 62 days.
An evaluation of the effect of VERU-111 on SARS-CoV-2 (COVID-19) compared to the placebo control will be evaluated after the last subject has completed Day 22. This will allow for the decision to move to Phase 3 more quickly if the Phase 2 portion of the study shows a clinically relevant difference in the proportion of subjects that are alive without respiratory failure at Day 22 in the VERU-111 treated groups compared to the Placebo treatment group and VERU-111 is well tolerated in the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth
-
-
Minnesota
-
Saint Louis Park, Minnesota, United States, 55426
- Methodist Hospital
-
Saint Paul, Minnesota, United States, 55101
- Regions Hospital
-
-
New Jersey
-
Vineland, New Jersey, United States, 08360
- Inspira Medical Center
-
-
Texas
-
Houston, Texas, United States, 77024
- Memorial Hermann Memorial City Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide informed consent
- Be able to communicate effectively with the study personnel
- Aged ≥18 years
- Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test
- Patients at high risk for ARDS, with known comorbidities for being at high risk, such as, Asthma (moderate to severe), Chronic Lung Disease, Diabetes, Chronic Kidney Disease being treated with dialysis, Severe Obesity (BMI ≥40), 65 years of age or older, primarily reside in a nursing home or long-term care facility, immunocompromised
- Peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air at screening
Subjects must agree to use acceptable methods of contraception
- If subject is female or the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
- If female subject or the female partner of a male subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
- If female subject or the female partner of a male subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
- Subject is willing to comply with the requirements of the protocol through the end of the study
Exclusion Criteria:
- Known hypersensitivity or allergy to colchicine
- Participation in any other clinical trial of an experimental treatment for COVID-19
- Concurrent treatment with other experimental agents with actual or possible direct acting antiviral activity against COVID-19 is prohibited < 24 hours prior to study drug dosing (except standard of care) Remdesivir and convalescent plasma is allowed as standard of care.
- Requiring mechanical ventilation at screening
- Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) >2 X upper limit of normal (ULN)
- Total bilirubin > ULN
- Creatinine clearance < 60 mL/min
- Documented medical history of liver disease, including but not limited to, prior diagnosis of hepatitis of any etiology, cirrhosis, portal hypertension, or confirmed or suspected esophageal varices
- Moderate to severe renal impairment
- Hepatic impairment
- Positive for HbsAg, or HCV antibodies at screening
- Any comorbid disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk
- Participants must agree to refrain from prolonged exposure to the sun or agree to use at least SPF 50 on all exposed skin and protective clothing during prolonged sun exposure throughout participation in this study and/or treatment with VERU-111.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo capsules
|
Respiratory Distress Syndrome, Adult
Other Names:
|
Experimental: Veru-111 18 mg
Veru-111 18mg capsules
|
Respiratory Distress Syndrome, Adult
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects That Are Alive Without Respiratory Failure at Day 29.
Time Frame: Day 29
|
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 29.
Respiratory failure is defined as endotracheal intubation and mechanical ventilation, extracorporeal membrane oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision making is driven solely by resource limitation
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
World Health Organization Ordinal Scale Clinical Improvement
Time Frame: Day 29
|
Improvement on the World Health Organization Ordinal Scale for Clinical Improvement. 8-point ordinal scale (WHO scale from 0 to 8). Lower value equals better while higher value equals worse Score of 0 Uninfected No clinical or virologic evidence of infection Score of 1 Ambulatory No limitation of activities Score of 2 Limitation of activities Score of 3 Hospitalized, no oxygen therapy Score of 4 Oxygen by mask or nasal prongs Score of 5 Non-invasive ventilation or high-flow oxygen Score of 6 Intubation and mechanical ventilation Score of 7 Ventilation + additional organ support - pressors, RRT, ECMO Score of 8 Death |
Day 29
|
Proportion of Subjects With Fever Normalization and SPO2 Greater Than 94% by Visit
Time Frame: Day 15, Day 22 and Day 29
|
Proportion of subjects with normalization of fever and oxygen saturation through. Responders are subjects who have been discharged from the hospital or has fever normalization maintained for at least 24 hours AND peripheral capillary oxygen saturation (SPO2) greater than 94% sustained for 24 hours is observed at the time of the visit. Non-responders are subjects who died before the visit or do not meet both criteria of the end point at the time of the visit. |
Day 15, Day 22 and Day 29
|
Proportion of Subjects Alive and Discharged From Hospital by Visit
Time Frame: Day 15, Day 22 and Day 29
|
Proportion of subjects alive and discharged from hospital by visit.
Responders are subjects who are alive and have been discharged from the hospital at the time of the visit.
(Non-responders are subjects who died before the visit or in the hospital at the time of the visit).
|
Day 15, Day 22 and Day 29
|
Patients Alive and Free of Respiratory Failure
Time Frame: Day 15 and Day 22
|
Proportion of patients alive and free or respiratory failure
|
Day 15 and Day 22
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Barnette, Veru Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- Severe Acute Respiratory Syndrome
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- V0211901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Adult
-
Wolfson Medical CenterUnknown
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Chang Gung Memorial HospitalUnknownRespiratory Distress Syndrome, AdultTaiwan
Clinical Trials on Veru-111
-
Veru Inc.TerminatedMetastatic Castration Resistant Prostate CancerUnited States
-
Veru Inc.CompletedSARS-CoV InfectionUnited States, Argentina, Brazil, Bulgaria, Colombia, Mexico
-
Veru Inc.TerminatedMetastatic Castration-resistant Prostate Cancer | Androgen Resistant Prostatic CancerUnited States
-
Veru Inc.WithdrawnMetastatic Triple Negative Breast Cancer
-
Veru Inc.TerminatedAdvanced Prostate AdenocarcinomaUnited States
-
Qlaris Bio, Inc.RecruitingGlaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)United States
-
SensorionCompletedAcute Unilateral Vestibulopathy (AUV)United States, Israel, France, Korea, Republic of, Hungary, Germany, Czechia, Italy
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsUnknownAdvanced and/or Metastatic Solid Organ CancerUnited States
-
REGENXBIO Inc.Active, not recruitingHurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)United States, Brazil, Israel